Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

PD-L1 checkpoint blockade delivered by retroviral replicating vector confers anti-tumor efficacy in murine tumor models.

Mitchell LA, Yagiz K, Hofacre A, Viaud S, Munday AW, Espinoza FL, Mendoza D, Rodriguez-Aguirre ME, Bergqvist S, Haghighi A, Miner MV, Accomando WP, Burrascano C, Gammon D, Gruber HE, Jolly DJ, Lin AH.

Oncotarget. 2019 Mar 19;10(23):2252-2269. doi: 10.18632/oncotarget.26785. eCollection 2019 Mar 19.

2.

Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory.

Viaud S, Ma JSY, Hardy IR, Hampton EN, Benish B, Sherwood L, Nunez V, Ackerman CJ, Khialeeva E, Weglarz M, Lee SC, Woods AK, Young TS.

Proc Natl Acad Sci U S A. 2018 Nov 13;115(46):E10898-E10906. doi: 10.1073/pnas.1810060115. Epub 2018 Oct 29.

3.

Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC.

Besse B, Charrier M, Lapierre V, Dansin E, Lantz O, Planchard D, Le Chevalier T, Livartoski A, Barlesi F, Laplanche A, Ploix S, Vimond N, Peguillet I, Théry C, Lacroix L, Zoernig I, Dhodapkar K, Dhodapkar M, Viaud S, Soria JC, Reiners KS, Pogge von Strandmann E, Vély F, Rusakiewicz S, Eggermont A, Pitt JM, Zitvogel L, Chaput N.

Oncoimmunology. 2015 Aug 12;5(4):e1071008. eCollection 2016 Apr.

4.

Microbiota modulation of myeloid cells in cancer therapy.

Goldszmid RS, Dzutsev A, Viaud S, Zitvogel L, Restifo NP, Trinchieri G.

Cancer Immunol Res. 2015 Feb;3(2):103-9. doi: 10.1158/2326-6066.CIR-14-0225. Review.

5.

Cancer and the gut microbiota: an unexpected link.

Zitvogel L, Galluzzi L, Viaud S, Vétizou M, Daillère R, Merad M, Kroemer G.

Sci Transl Med. 2015 Jan 21;7(271):271ps1. doi: 10.1126/scitranslmed.3010473. Review.

6.

The role of the microbiota in inflammation, carcinogenesis, and cancer therapy.

Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G.

Eur J Immunol. 2015 Jan;45(1):17-31. doi: 10.1002/eji.201444972. Epub 2014 Nov 13. Review.

7.

Harnessing the intestinal microbiome for optimal therapeutic immunomodulation.

Viaud S, Daillère R, Boneca IG, Lepage P, Pittet MJ, Ghiringhelli F, Trinchieri G, Goldszmid R, Zitvogel L.

Cancer Res. 2014 Aug 15;74(16):4217-21. doi: 10.1158/0008-5472.CAN-14-0987. Epub 2014 Jul 29. Review.

8.

Dendritic cell-derived exosomes as immunotherapies in the fight against cancer.

Pitt JM, Charrier M, Viaud S, André F, Besse B, Chaput N, Zitvogel L.

J Immunol. 2014 Aug 1;193(3):1006-11. doi: 10.4049/jimmunol.1400703. Review.

9.

Gut microbiome and anticancer immune response: really hot Sh*t!

Viaud S, Daillère R, Boneca IG, Lepage P, Langella P, Chamaillard M, Pittet MJ, Ghiringhelli F, Trinchieri G, Goldszmid R, Zitvogel L.

Cell Death Differ. 2015 Feb;22(2):199-214. doi: 10.1038/cdd.2014.56. Epub 2014 May 16. Review.

10.

Why should we need the gut microbiota to respond to cancer therapies?

Viaud S, Daillère R, Yamazaki T, Lepage P, Boneca I, Goldszmid R, Trinchieri G, Zitvogel L.

Oncoimmunology. 2014 Jan 1;3(1):e27574. Epub 2014 Jan 17.

11.

The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide.

Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillère R, Hannani D, Enot DP, Pfirschke C, Engblom C, Pittet MJ, Schlitzer A, Ginhoux F, Apetoh L, Chachaty E, Woerther PL, Eberl G, Bérard M, Ecobichon C, Clermont D, Bizet C, Gaboriau-Routhiau V, Cerf-Bensussan N, Opolon P, Yessaad N, Vivier E, Ryffel B, Elson CO, Doré J, Kroemer G, Lepage P, Boneca IG, Ghiringhelli F, Zitvogel L.

Science. 2013 Nov 22;342(6161):971-6. doi: 10.1126/science.1240537.

12.

Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines.

Hannani D, Locher C, Yamazaki T, Colin-Minard V, Vetizou M, Aymeric L, Viaud S, Sanchez D, Smyth MJ, Bruhns P, Kroemer G, Zitvogel L.

Cell Death Differ. 2014 Jan;21(1):50-8. doi: 10.1038/cdd.2013.60. Epub 2013 Jun 7.

13.

Comparison of two shampoos as sole treatment for canine bacterial overgrowth syndrome.

Viaud S, Maynard L, Sanquer A.

Vet Rec. 2012 Jun 30;170(26):675. doi: 10.1136/vr.100643. Epub 2012 Jun 7.

PMID:
22678617
14.

Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells.

Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, Chen L, Mécheri S, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Degli-Esposti M, Chaput N, Zitvogel L.

Cancer Res. 2012 Jun 1;72(11):2757-67. doi: 10.1158/0008-5472.CAN-11-3379. Epub 2012 Mar 16.

15.

Comparison of two shampoos for the treatment of canine Malassezia dermatitis: a randomised controlled trial.

Maynard L, Rème CA, Viaud S.

J Small Anim Pract. 2011 Nov;52(11):566-72. doi: 10.1111/j.1748-5827.2011.01124.x. Epub 2011 Oct 10.

PMID:
21985533
16.

IL-18 induces PD-1-dependent immunosuppression in cancer.

Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, Prévost-Blondel A, Kato M, Schultze JL, Tartour E, Kroemer G, Chaput N, Zitvogel L.

Cancer Res. 2011 Aug 15;71(16):5393-9. doi: 10.1158/0008-5472.CAN-11-0993. Epub 2011 Jul 1.

17.

Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.

Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L.

Semin Immunopathol. 2011 Jul;33(4):369-83. doi: 10.1007/s00281-011-0245-0. Epub 2011 May 25. Review.

PMID:
21611872
18.

An inhibitor of cyclin-dependent kinases suppresses TLR signaling and increases the susceptibility of cancer patients to herpesviridae.

Zoubir M, Flament C, Gdoura A, Bahleda R, Litvinova E, Soumelis V, Conforti R, Viaud S, Soria JC, Kroemer G, Zitvogel L, Chaput N.

Cell Cycle. 2011 Jan 1;10(1):118-26. Epub 2011 Jan 1.

PMID:
21200142
19.

Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ.

Viaud S, Ploix S, Lapierre V, Théry C, Commere PH, Tramalloni D, Gorrichon K, Virault-Rocroy P, Tursz T, Lantz O, Zitvogel L, Chaput N.

J Immunother. 2011 Jan;34(1):65-75. doi: 10.1097/CJI.0b013e3181fe535b.

PMID:
21150714
20.

Cyclophosphamide induces differentiation of Th17 cells in cancer patients.

Viaud S, Flament C, Zoubir M, Pautier P, LeCesne A, Ribrag V, Soria JC, Marty V, Vielh P, Robert C, Chaput N, Zitvogel L.

Cancer Res. 2011 Feb 1;71(3):661-5. doi: 10.1158/0008-5472.CAN-10-1259. Epub 2010 Dec 9.

21.

Dendritic cell-derived exosomes for cancer immunotherapy: what's next?

Viaud S, Théry C, Ploix S, Tursz T, Lapierre V, Lantz O, Zitvogel L, Chaput N.

Cancer Res. 2010 Feb 15;70(4):1281-5. doi: 10.1158/0008-5472.CAN-09-3276. Epub 2010 Feb 9. Review.

22.

Opposing effects of toll-like receptor (TLR3) signaling in tumors can be therapeutically uncoupled to optimize the anticancer efficacy of TLR3 ligands.

Conforti R, Ma Y, Morel Y, Paturel C, Terme M, Viaud S, Ryffel B, Ferrantini M, Uppaluri R, Schreiber R, Combadière C, Chaput N, André F, Kroemer G, Zitvogel L.

Cancer Res. 2010 Jan 15;70(2):490-500. doi: 10.1158/0008-5472.CAN-09-1890. Epub 2010 Jan 12.

23.

Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha.

Viaud S, Terme M, Flament C, Taieb J, André F, Novault S, Escudier B, Robert C, Caillat-Zucman S, Tursz T, Zitvogel L, Chaput N.

PLoS One. 2009;4(3):e4942. doi: 10.1371/journal.pone.0004942. Epub 2009 Mar 25.

24.

The Janus face of dendritic cells in cancer.

Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L.

Oncogene. 2008 Oct 6;27(45):5920-31. doi: 10.1038/onc.2008.270. Review.

PMID:
18836473
25.

Exosomes for the treatment of human malignancies.

Viaud S, Ullrich E, Zitvogel L, Chaput N.

Horm Metab Res. 2008 Feb;40(2):82-8. doi: 10.1055/s-2007-1022548. Review.

PMID:
18283625
26.

Selective resistance of tetraploid cancer cells against DNA damage-induced apoptosis.

Castedo M, Coquelle A, Vitale I, Vivet S, Mouhamad S, Viaud S, Zitvogel L, Kroemer G.

Ann N Y Acad Sci. 2006 Dec;1090:35-49.

PMID:
17384245
27.

Therapy-induced tumor immunosurveillance involves IFN-producing killer dendritic cells.

Ullrich E, Bonmort M, Mignot G, Chaput N, Taieb J, Ménard C, Viaud S, Tursz T, Kroemer G, Zitvogel L.

Cancer Res. 2007 Feb 1;67(3):851-3. Review.

28.

Dendritic cell derived-exosomes: biology and clinical implementations.

Chaput N, Flament C, Viaud S, Taieb J, Roux S, Spatz A, André F, LePecq JB, Boussac M, Garin J, Amigorena S, Théry C, Zitvogel L.

J Leukoc Biol. 2006 Sep;80(3):471-8. Epub 2006 Jun 29. Review.

PMID:
16809645
29.

Macrophage activation switching: an asset for the resolution of inflammation.

Porcheray F, Viaud S, Rimaniol AC, Léone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G.

Clin Exp Immunol. 2005 Dec;142(3):481-9.

Supplemental Content

Support Center